Invention Grant
US09546150B2 Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7
有权
用于抑制泛素特异性蛋白酶的取代喹唑啉-4-酮7
- Patent Title: Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7
- Patent Title (中): 用于抑制泛素特异性蛋白酶的取代喹唑啉-4-酮7
-
Application No.: US14241923Application Date: 2012-08-29
-
Publication No.: US09546150B2Publication Date: 2017-01-17
- Inventor: Frédéric Colland , Marie-Edith Gourdel
- Applicant: Frédéric Colland , Marie-Edith Gourdel
- Applicant Address: FR Paris
- Assignee: HYBRIGENICS SA
- Current Assignee: HYBRIGENICS SA
- Current Assignee Address: FR Paris
- Agency: Stites & Harbison, PLLC
- Agent B. Aaron Schulman, Esq.
- Priority: EP11306096 20110902
- International Application: PCT/EP2012/066741 WO 20120829
- International Announcement: WO2013/030218 WO 20130307
- Main IPC: A61K31/517
- IPC: A61K31/517 ; C07D239/88 ; C07D401/06 ; C07D409/14 ; C07D239/91 ; A61K45/06
Abstract:
The present invention relates to quinazolin-4-one compounds of formula (I′), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
Public/Granted literature
- US20140371247A1 Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 Public/Granted day:2014-12-18
Information query
IPC分类:
